Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (Diluted Average) (2019 - 2025)

Editas Medicine (EDIT) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $90.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 9.54% to $90.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.1 million, a 9.54% increase, with the full-year FY2024 number at $82.3 million, up 8.39% from a year prior.
  • Shares Outstanding (Diluted Average) was $90.1 million for Q3 2025 at Editas Medicine, up from $84.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $90.1 million in Q3 2025 to a low of $66.0 million in Q1 2021.
  • A 5-year average of $74.7 million and a median of $71.4 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 0.59% in 2022, then rose 18.88% in 2024.
  • Editas Medicine's Shares Outstanding (Diluted Average) stood at $67.6 million in 2021, then increased by 1.55% to $68.7 million in 2022, then increased by 10.63% to $76.0 million in 2023, then increased by 8.39% to $82.3 million in 2024, then increased by 9.42% to $90.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Shares Outstanding (Diluted Average) are $90.1 million (Q3 2025), $84.4 million (Q2 2025), and $83.1 million (Q1 2025).